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Abstract
Blood glucose homeostasis between meals depends upon production of glucose within the endoplasmic reticulum (ER) of
the liver and kidney by hydrolysis of glucose-6-phosphate (G6P) into glucose and phosphate (Pi). This reaction depends on
coupling the G6P transporter (G6PT) with glucose-6-phosphatase-a (G6Pase-a). Only one G6PT, also known as SLC37A4, has
been characterized, and it acts as a Pi-linked G6P antiporter. The other three SLC37 family members, predicted to be sugar-
phosphate:Pi exchangers, have not been characterized functionally. Using reconstituted proteoliposomes, we examine
the antiporter activity of the other SLC37 members along with their ability to couple with G6Pase-a. G6PT- and mock-
proteoliposomes are used as positive and negative controls, respectively. We show that SLC37A1 and SLC37A2 are ER-
associated, Pi-linked antiporters, that can transport G6P. Unlike G6PT, neither is sensitive to chlorogenic acid, a competitive
inhibitor of physiological ER G6P transport, and neither couples to G6Pase-a. We conclude that three of the four SLC37
family members are functional sugar-phosphate antiporters. However, only G6PT/SLC37A4 matches the characteristics of
the physiological ER G6P transporter, suggesting the other SLC37 proteins have roles independent of blood glucose
homeostasis.
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Introduction
The glucose-6-phosphate transporter (G6PT, also known as
SLC37A4) is localized in the endoplasmic reticulum (ER)
membrane [1,2], where it acts as a phosphate (Pi)-linked, glucose-
6-phosphate (G6P) antiporter [3]. The primary function of G6PT is
to translocate G6P from the cytoplasm into the lumen of the ER for
hydrolysis into glucose and Pi. The hydrolysis is catalyzed by a
second ER membrane protein, glucose-6-phosphatase-a (G6Pase-a
or G6PC), which has its active site localized within the lumen
of the ER [4]. Together, the G6PT/G6Pase-a complex maintains
interprandial glucose homeostasis. Deficiencies in G6PT cause
glycogen storage disease type Ib (GSD-Ib) and deficiencies in
G6Pase-a cause GSD-Ia [5,6]. Both disorders manifest a metabolic
phenotype of impaired glucose homeostasis [5,6]. Notably, the
G6PT activity is sensitive to inhibition by chlorogenic acid (CHA)
[7]. Studies have also shown that G6PT-mediated microsomal G6P
uptake activity requires an active G6Pase-a [8]. Hepatic micro-
somes prepared from G6Pase-a-deficient (GSD-Ia) mice, which still
possess an intact G6PT, exhibit markedly lower G6P uptake activity
compared to wild type hepatic microsomes [8]. However, this can
be reversed if G6Pase-a activity is restored in the GSD-Ia mouse
livers via gene transfer studies [9]. Based on these characteristics,
functional assays to detect physiologically important G6PT activity
have been developed [10–12].
The solute carrier 37 (SLC37) family consists of 4 proteins,
SLC37A1 [13–15], SLC37A2 [15–17], SLC37A3 [15] and
G6PT/SLC37A4 [5,6,15]. With the exception of G6PT, which
was shown to function as a Pi-linked G6P antiporter [3], none of
the other SLC37 proteins has been functionally characterized.
Their grouping into the SLC37 family is based on sequence
homology to bacterial organo-phosphate:Pi exchangers [15].
SLC37A1 was cloned based on its similarity to the glycerol-3-
phosphate transporter [13]. While SLC37A2 and SLC37A3 have
no known substrates preferences, their similarity to G6PT/
SLC37A4 suggests G6P might be a good candidate. In further
support of this hypothesis, Leuzzi et al. [18] have shown that there
is more than one G6P transport activity present in microsomes
prepared from human fibroblasts and HeLa cells, and that these
can be differentiated by their sensitivity to CHA. Only G6PT/
SLC37A4 has been linked to a genetic disorder [5,6]. SLC37A1
was not found to be mutated in patients with glycerol kinase
deficiency, and despite mapping to the critical region of the
autosomal recessive deafness locus, DFNB10 on chromosome
21q22.3, mutation analyses excluded it as the gene for DFNB10
[13]. Therefore, beyond the structural similarity, there is a need to
understand the functional similarities of these proteins to gain
insight into their biological roles. The first aims of this study were
to establish whether the other SLC37 family members, SLC37A1,
SLC37A2, and SLC37A3 are associated with the ER membrane
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proposed to examine those ER-associated G6P transporters to
determine if they can form a functional complex with G6Pase-a
capable of hydrolyzing G6P to glucose; and if their activity is
sensitivity to CHA. We show that both SLC37A1 and SLC37A2
meet the first criteria, however, unlike G6PT, neither is sensitive to
inhibition by CHA and neither can couple functionally to G6Pase-
a. In contrast, SLC37A3 is not a G6P transporter. Taken together
these findings suggest that only SCL37A4 contributes to inter-
prandial blood glucose homeostasis.
Materials and Methods
Construction of recombinant adenoviruses
The SLC37A1, SLC37A2 or SLC37A3 constructs were
generated by PCR using the respective cDNA clones (Invitrogen,
Carlsbad, CA) as templates. A sequence encoding the eight-amino-
acid Flag marker peptide, DYKDDDDK (Scientific Imaging
Systems, Eastman Kodak, CT) was added at the 59 end of each
construct, and the resulting DNA cloned into the pAdlox vector
[19]. The nucleotide sequence in all constructs was verified by
DNA sequencing. The recombinant adenovirus (Ad) was gener-
ated by the Cre-lox recombination system [19], resulting in Ad-
SLC37A1-5Flag, Ad-SLC37A2-5Flag, and Ad-SLC37A3-5Flag.
Recombinant Ad, Ad-G6PT, Ad-G6PT-5Flag, Ad-G6Pase-a, and
Ad-G6Pase-b have been described previously [4,12,20]. Each
recombinant virus was plaque purified and amplified to produce
viral stocks with titers of approximately 1 to 3610
10 plaque
forming unit (PFU) per ml.
Expression in COS-1 cells and microsomal G6P uptake
assay
COS-1 cells were plated in 150-cm
2 flasks and grown at 37uCi n
HEPES-buffered Dulbecco’s modified minimal essential medium
supplemented with 4% fetal bovine serum. The multiplicity of
infection (MOI) for Ad-G6PT, Ad-SLC37A1-5Flag, Ad-SLC37A2-
5Flag, or Ad-SLC37A3-5Flag was 50 PFU/cell and MOI for Ad-
G6Pase-a or Ad-G6Pase-b was 25 PFU/cell. Mock infected COS-1
cells were used as controls. After incubation at 37uC for 24 h, the
infected cultures were used for microsome isolation, proteoliposome
reconstitution, and Western-blot analysis.
Microsomal G6P uptake measurements were performed
essentially as described previously [10–12]. Microsomes (40 mg)
were incubated in a reaction mixture (100 ml) containing 50 mM
sodium cacodylate buffer, pH 6.5, 250 mM sucrose, and 0.2 mM
[U-
14C]G6P (50 mCi/mmol, American Radiolabeled Chemicals,
St Louis, MO). The reaction was stopped at the appropriate time
by filtering through a nitrocellulose membrane (0.45 mm,
Millipore Co., Billerica, MA), then washing with an ice-cold
solution containing 50 mM Tris-HCl, pH 7.4 and 250 mM




4/chamber) in a 2-chambered coverglass
(Nalge Nunc International Co, Naperville, IL) were infected with
Ad-SLC37A1-5Flag, Ad-SLC37A2-5Flag, Ad-SLC37A3-5Flag, or
Ad-G6PT-5Flag at MOI of 0.1 PFU/cell. After incubation at
37uC for 1 day, the infused cells were fixed for 10 min at 25uCi n
3.7% formaldehyde in PBS, then permeabilized with 0.2% (v/v)
Triton X-100 for 15 min at 25uC. After blocking with 5% (v/v)
goat serum in PBS for 1 h at 25uC, the cells were incubated
overnight at 4uC in PBS containing 5% goat serum with either a
mouse monoclonal antibody against the Flag epitope (Sigma, St.
Louis, MO), or a rabbit polyclonal antibody against calreticulin
(Santa Cruz Biotechnology, Santa Cruz, CA). After washes with
PBS, the cells were incubated for 1 h at 25uC in the dark, in PBS
containing 5% goat serum with either goat anti-mouse or anti-
rabbit antibody conjugated with Alexa Fluor 555 or 488
(Invitrogen, Carlsbad, CA) respectively. After washing with PBS,
the cells were mounted with an anti-fade, water-based mount-
ing medium containing DAPI (Vector Lab, Burlingame, GA),
observed with an Axioskop 2 plus fluorescence microscope (Carl
Zeiss, Thornwood, NY) and the images digitized using AxioVision
4.3 (Carl Zeiss). Co-localization of green fluorescent calreticulin
and red fluorescent SLC37 protein results in a yellow fluorescence.
Solubilization and reconstitution of membrane proteins
Solubilization of microsomal membrane proteins was per-
formed as described previously [21–23]. Membrane proteins were
solubilized on ice by mixing 2 mg of microsomes in 1 ml of a
solution containing: 20 mM Tris-HCl, pH 7.5; 20% glycerol;
1.25% (w/v) n-octyl-b-D-glucopyranoside octylglucoside (Calbio-
chem, San Diego, CA); 2 mM DTT; 1% aprotinin; 1 mM AE-
BSF; 2 mg/ml pepstatin A; 2 mg/ml leupeptin (all inhibitors from
Roche Diagnostics, Indianapolis, IN); and 0.4% (w/v) lipid
mixture. The lipid mixture consisted of: E coli polar lipid extract,
L-a phosphotidylcholine, L-a phosphotidylserine, and cholesterol
combined in a ratio of 60:17.5:10:12.5 w/w (all from Avanti Polar
lipids, Inc, Alabaster, AL) dissolved in 2 mM b-mercaptoethanol.
After 20 min gently stirring, the insoluble materials were pelleted
by centrifugation at 170,2006g for 60 min at 4uC. Aliquots of the
clear supernatant were stored at 270uC.
Proteoliposome reconstitution was performed as previously
described [21–23]. The lipid mixture (45 mg/ml) was sonicated in
a bath-type sonicator (Laboratory Supplies Inc, Hicksville, NY) at
18–23uC until the solution appeared clear, as described previously
[22]. The detergent solubilized microsomal membrane extracts
(500 to 700 mg) were mixed with the sonicated lipid mixture at a
ratio of 1:10 protein:lipid (w/w) to a final volume of ,1 ml and
the reaction brought to a final volume of 4 ml by the addition of
octylglucoside dilution buffer (100 mM KPO4, pH 7.5, 1.25%
octylglucoside, 2 mM DTT, and 1% aprotinin). After mixing, the
suspension was placed on ice for 20 min before being placed
inside a dialysis cassette (PIERCE, Rockford, IL). For Pi-loaded
proteoliposomes, dialysis was performed overnight at 4uC against
a phosphate buffer (20 or 50 mM KH2PO4, pH 7.0, 1 mM DTT,
and protease inhibitors). For MOPS-loaded proteoliposones,
dialysis was performed overnight at 4uC against a MOPS/K
buffer (20 mM MOPS, pH 7.5 adjusted with KOH; 75 mM
K2SO4; 2.5 mM MgSO4, 1 mM DTT, and protease inhibitors).
The resulting proteoliposomes were pelleted by centrifugation at
170,2006 g for 60 min 4uC, resuspended in 200 ml MOPS/K
buffer, and used in transport assays. Proteoliposomes prepared
from detergent solubilized microsomal membrane extracts of
mock-infected cells were used as negative controls. The protein
content in microsomes, detergent extract, and proteoliposomes
was quantified by the Amido Black B protein estimation method as
described previously [24].
Western-blot analysis
For Western-blot analysis, proteins were resolved by electro-
phoresis through a 10% polyacrylamide-SDS gel and trans-blotted
onto polyvinylidene fluoride membranes (Millipore). The mem-
branes were incubated overnight with a rabbit polyclonal antibody
against G6PT [12] or a mouse monoclonal antibody against the
Flag epitope (Sigma-Alorich, St. Louis, MO). The membranes
were then incubated with the appropriate horseradish peroxidase-
SLC37A1 and SLC37A2 Are Antiporters
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using the Immobilon western chemiluminescent HRP substrate
(Millipore).
Proteoliposomal transport assays
Proteoliposomal transport assays were performed at room
temperature for various lengths of time using reaction mixtures
containing 20 mM MOPS/K buffer, 25 mg/ml proteoliposomes,
and either 0.1 mM [U-
14C]G6P (50 mCi/mmol) or 0.5 mM
32Pi.
The
32Pi was prepared by boiling carrier-free
32Pi (MP Bio-
chemical, Irvine, CA) in 1 ml of 1 N HCl for 3 h and diluting with
an equal volume of 2 M K2HPO4 as described previously [25]. At
each of the assay time points, 100 ml aliquots were withdrawn,
filtered immediately through presoaked 0.22 mm nitrocellulose
filters (Millipore), and washed with 20 mM MOPS/K buffer. The
dried filters were then counted in a liquid scintillation counter.
Inhibition of G6P or Pi transport by CHA (Sigma-Alorich) [7] or
vanadate [26] was examined in reaction mixtures containing
20 mM MOPS/K buffer 25 mg/ml of 50 mM Pi,-loaded G6PT-,
SLC37A1- or SLC37A2-proteoliposomes, 0.1 mM [U-
14C]G6P
or 0.5 mM
32Pi, and the respective inhibitor. After incubation at
room temperature for 3 min, the reaction mixture was filtered and
counted as described above.
Real time PCR analysis
Total RNAs were isolated using TRIzol Reagent (Invitrogen).
The mRNA expression was quantified by real-time RT-PCR, in
triplicate, in an Applied Biosystems 7300 Real-Time PCR System
using the gene-specific TaqManH Gene Expression Assays and
then normalized to b-actin RNA. The Applied Biosystems probes
were: G6PT, Mm00484574_m1; SLC37A1, Mm00461949_m1;
SLC37A2, Mm00451435_m1, SLC37A3, Mm00551183_m1 and
b-actin, Mm00607939_s1.
Statistical analysis
The unpaired t test was performed using the GraphPad Prism
Program, version 4 (GraphPad Software, San Diego, CA). Values
were considered statistically significant at p,0.05.
Results
The SLC37 members are ER-associated proteins
To determine the cellular localization of SLC37A2 and
SLC37A3, COS-1 cells were infected with either Ad-SLC37A2-
5Flag or Ad-SLC37A3-5Flag and visualized by double immuno-
staining for the Flag-tag and the ER-marker protein calreticulin
[27]. Ad-SLC37A1-5Flag and Ad-G6PT-5Flag were used as
positive controls. SLC37A2 and SLC37A3, co-localized with
calreticulin (Figure 1) in the same manner as the positive controls,
demonstrating their association with the ER.
SLC37A1 and SLC37A2 but not SLC37A3 are Pi-linked G6P
antiporters
To examine the G6P transport activity of SLC37A1, SLC37A2
and SLC37A3, proteoliposomes were reconstituted from detergent
solubilized microsomal membrane extracts isolated from COS-1
cells infected with Ad-SLC37A1-5Flag, Ad-SLC37A2-5Flag, or
Ad-SLC37A3-5Flag. Proteoliposomes reconstituted from mock- or
Ad-G6PT-infected COS-1 cells were used as negative and positive
controls, respectively. Microsome solubilization and proteolipo-
some reconstitution were monitored by Western blot analysis using
an antibody against the Flag tag or G6PT [12] (Figure 2A).
The G6P uptake activity was measured in SLC37A1-,
SLC37A2-, or SLC37A3-proteoliposomes loaded with 50 mM
Pi. The Pi-loaded G6PT and mock proteoliposomes were used as
positive and negative controls, respectively. As shown in an earlier
study [3], labeled G6P was taken up efficiently into G6PT-
proteoliposomes but not into mock-proteoliposomes (Figure 2B).
G6P was also taken up efficiently in SLC37A1-proteoliposomes
and SLC37A2-proteoliposomes (Figure 2B). In contrast, G6P
transport activity in SLC37A3-proteoliposomes was indistinguish-
able from the activity of the mock-proteoliposomes (Figure 2B).
For Pi uptake assays, proteoliposomes were loaded with 50 mM
Pi. Again, labeled Pi was taken up efficiently into SLC37A1- and
SLC37A2 and the control G6PT-proteoliposomes (Figure 2B). Pi
uptake activity into SLC37A3-proteoliposomes was indistinguish-
able from the mock-proteoliposomes.
Consistent with the findings for G6PT [3], the rates of G6P
or Pi uptake correlated with the concentrations of Pi loaded in
SLC37A1- or SLC37A2-proteoliposomes (Figure 3A). The anti-
porter activity was then examined in 50 mM Pi-loaded SLC37A1-
or SLC37A2-proteoliposomes by external G6P or Pi. As expected,
G6P uptake was marked inhibited by the addition of external Pi
and Pi uptake was markedly inhibited by the addition of external
G6P (Figure 3B).
To further elucidate antiporter activity of SLC37A1 and
SLC37A2, we examined the effects of vanadate, a close structural
and chemical mimic of Pi [26]. Vanadate inhibits G6P transport in
hepatic microsomes [8] and Pi-loaded G6PT-proteoliposomes [3].
The G6P and Pi uptake activity in Pi-loaded SLC37A1- or
SLC37A2-proteoliposomes was also sensitive to inhibition by
vanadate (Figure 3C).
Relative expression levels of SLC37 members in the liver,
kidney, intestine, and pancreas
The liver and kidney play key roles in G6P metabolism and
glucose homeostasis therefore any G6P transporters implicated in
blood glucose homeostasis must be expressed in these organs. The
intestine and pancreas also play roles in the control of glucose
homeostasis [28,29] and might similarly be expected to express
the G6P transporters. We therefore examined the relative mRNA
levels of the SLC37 members in the liver, kidney, intestine and
pancreas. Quantitative RT-PCR analysis showed that in the liver,
kidney, and intestine, G6PT transcripts were present at the highest
levels and SLC37A2 at the lowest levels (Table 1). In the kidney,
SLC37A3, which lacks G6P antiporter activity was expre-
ssed second to G6PT and in the intestine both SLC37A1 and
SLC37A3 were expressed at significantly high levels (Table 1). In
the pancreas, SLC37A3 transcripts were present at the highest
levels, followed by G6PT, SLC37A1, and SLC37A2 (Table 1).
The antiporter activity of SLC37A1 and SLC37A2 is
insensitive to inhibition by CHA
We then examined the effects of CHA, a specific inhibitor of
G6P transport in the liver and kidney [7], on the antiporter
activity of SLC37A1 and SLC37A2. As shown in earlier studies,
G6P and Pi uptake in Pi-loaded G6PT-proteoliposomes was
markedly inhibited by CHA (Figure 4). Interestingly, this inhibitor
had no effects on G6P or Pi uptake in Pi-loaded SLC37A1- or
SLC37A2-proteoliposomes (Figure 4).
SLC37A1 and SLC37A2 cannot functionally couple with
G6Pase-a or G6Pase-b
To examine coupling between the SLC37 transporters and
G6Pase-a or G6Pase-b, we compared G6P uptake activity of
SLC37A1 and SLC37A2 Are Antiporters
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e23157microsomes expressing SLC37A1 or SLC37A2 in the presence
or absence of G6Pase-a or G6Pase-b. Microsomes expressing
SLC37A1, SLC37A2, or G6PT exhibited low levels of G6P
transport activity (Figure 5). When co-expressed with G6Pase-a or
G6Pase-b, both SLC37A1 and SLC37A2 showed little increase in
G6P uptake activity. In contrast, the positive control microsomes
co-expressing G6PT with G6Pase-a or co-expressing G6PT with
G6Pase-b exhibited a markedly increased G6P uptake activity
(Figure 5). As was shown in earlier studies [20], G6P uptake
activity in microsomes co-expressing G6PT/G6Pase-a was 4.7-
fold higher than the activity in microsomes co-expressing G6PT/
G6Pase-b (Figure 5).
Discussion
The solute-carrier (SLC) gene superfamily of membrane-bound
transporters are organized into 55 gene families based largely on
protein sequence homology and predicted substrate specificity
[30]. The SLC37 family consists of 4 members, SLC37A1 through
SLC37A4, named either organo-phosphate:Pi or sugar-phospha-
te:Pi exchangers [15]. While human SLC37A1 was originally
isolated based on its similarity to E. coli glycerol-3-phosphate
transporter, it was not found to be mutated in patients with
glycerol kinase deficiency [13], suggesting glycerol-3-phosphate
may not be its primary substrate. Despite this, there have been no
functional assays to determine the substrate activity of SLC37A1.
In contrast, SLC37A4, which was isolated independently both by
homology to sequences of bacterial phosphate ester transporters
[31] and by linkage analysis in GSD-Ib patients [32], has been
extensively characterized genetically and functionally. The role of
SLC37A4, more commonly called G6PT, is as a Pi-linked G6P
antiporter [3] that transports the G6P substrate from the
cytoplasm into the ER lumen where the enzyme G6Pase-a
hydrolyzes it to glucose and Pi. The Pi released is in turn
transported out of the ER lumen into the cytoplasm by the
SLC37A4/G6PT antiporter activity [3]. In GSD-Ia and GSD-Ib
patients, failure to hydrolyze G6P into glucose in the liver and
kidney results in a loss of interprandial blood glucose homeostasis
[5,6]. Studies of hepatic microsomal G6P uptake from GSD-Ia
mice have demonstrated that G6P uptake activity depends not
only on G6PT, but also a functional coupling with G6Pase-a [8].
Microsomal G6P uptake activity is low in the absence of a
functional G6Pase-a [8] but is greatly increased when a functional
G6Pase-a is restored [9]. Studies have shown that there is no
stringent genotype-phenotype correlation in GSD-Ib patients [33],
suggesting the existence of a genetic modifier, probably another
G6P transporter. Supporting this, Leuzzi et al. [18] showed
additional G6P transport activities do exist in human cell lines.
Therefore the SLC37 family proteins are natural candidates for
the modifier/transporter, which may couple with G6Pase-a to
Figure 1. The SLC37 proteins are localized in the ER. Double immunofluorescence staining for SLC37A1, SLC37A2, SLC37A3, or G6PT (red
fluorescence), endogenous calreticulin (green fluorescence), and DAPI in COS-1 cells infected with Ad-SLC37A1-5Flag, Ad-SLC37A2-5Flag, Ad-
SLC37A3-5Flag, or Ad-G6PT-5Flag as described under Materials and Methods. Co-localization of SLC37 proteins with the ER-marker calreticulin is
indicated by yellow in the merged image.
doi:10.1371/journal.pone.0023157.g001
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homeostasis.
We set out to investigate if SLC37A1, SLC37A2 and/or
SLC37A3 are G6P transporters and if so whether they are capable
of coupling with G6Pase-a to impact blood glucose homeostasis.
Since glycogenolysis and gluconeogenesis, the predominant sources
of G6P in the cell, are cytoplasmic pathways, any candidate
transporter must be an ER associated membrane protein, able to
transport G6P into the lumen of the ER for the G6Pase-a activity.
SLC37A4/G6PT [1,2] and SLC37A1 [14] have been previously
demonstrated to be embedded in the ER. We now demonstrated
that SLC37A2 and SLC37A3 are similarly localized. Moreover the
accessibility of their N-terminal Flag motif in permeabilized cells to
the anti-Flag antibody also demonstrates that like SLC37A4 their
N-terminus is on the cytoplasmic side of the ER membrane.
Consistent with a previous demonstration that SLC37A4 has 10
transmembrane domains [1,2], the protein sequences of the other
SLC37 family members are also predicted to have between 10 and
12 domains. When assayed for G6P transport function, SLC37A1
and SLC37A2 both exhibited an activity similar to SLC37A4/
Figure 2. G6P and Pi uptake in SLC37 proteoliposomes. Microsomes were isolated from COS-1 cells infected with Ad-SLC37A1-5Flag, Ad-
SLC37A2-5Flag, Ad-SLC37A3-5Flag or Ad-G6PT and proteoliposomes were reconstituted from the respective detergent solubilized microsomal
membrane extracts as described under Materials and Methods. Results shown are from three independent experiments, each point determined in
triplicate. (A) Western-blot analysis of SLC37 proteins during reconstitution of proteoliposomes from the respective microsomal membranes using a
mouse monoclonal antibody against the Flag epitope or a rabbit polyclonal antibody against G6PT [12]. Each lane contains 10 mg protein. (B) G6P or
Pi uptake in 50 mM Pi -loaded SLC37A1-, SLC37A2-, SLC37A3-proteoliposomes. G6P or Pi uptake in 50 mM Pi -loaded G6PT- and mock-
proteoliposomes were used as controls.
doi:10.1371/journal.pone.0023157.g002
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despite its similarity to glycerol-3-phosphate transporter, SLC37A1
is a G6P transporter. Of the three G6P transporters, all are capable
of both heterologous G6P:Pi and homologous Pi:Pi exchanges
characteristic of SLC37A4/G6PT. While these are consistent with
theSLC37A1 andSLC37A2 beingpossible modifiers ofSLC37A4/
G6PT, neither protein was capable of coupling with G6Pase-a.
Moreover, while G6P transport activity responsible for blood
glucose homeostasis is known to be sensitive to CHA inhibition [7],
neither SLC37A1 nor SLC37A2 showed this sensitivity. Taken
together, our data suggest that SLC37A1 and SLC37A2 are not
implicated in blood glucose homeostasis.
This conclusion was further underlined by the expression
profiles of the proteins. Interprandial blood glucose homeostasis is
maintained predominantly by the release of glucose from G6P
produced in the terminal steps of gluconeogenesis and glycogen-
Figure 3. Effects of Pi loading, external G6P, Pi and vanadate on antiporter activity of SLC37 members. Proteoliposomes were
reconstituted from detergent solubilized microsomal membrane extracts isolated from Ad-SLC37A1-5Flag, Ad-SLC37A2-5Flag, or Ad-G6PT infected
COS-1 cells as described under Materials and Methods. Results shown are from three independent experiments, each point determined in triplicate.
(A) Effects of Pi -loading on G6P or Pi uptake activity of SLC37 proteoliposomes. The concentrations of Pi loaded were 50 mM, 20 mM, and 0 mM
(MOPS). (B) Inhibition of G6P uptake in 50 mM Pi-loaded SLC37 proteoliposomes by external Pi or inhibition of Pi uptake in 50 mM Pi-loaded SLC37
proteoliposomes by external G6P. (C) Effects of vanadate on G6P and Pi uptake activities of SLC37 proteoliposomes. Data are presented as the mean
6 SEM. *p,0.05; **p,0.005.
doi:10.1371/journal.pone.0023157.g003
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also play roles in glucose homeostasis [28,29]. While SLC37A3 is
expressed primarily in the kidney, liver, and intestine, and is the
second or third most abundant SLC37 transcript expressed in
those organs, after SLC37A4/G6PT, it is the member that lacks
G6P transport activity. SLC37A3 is also the most abundant
SLC37 transcript in the pancreas. Given the sequence similarities,
it is reasonable to expect SLC37A3 will have a sugar transport
activity of some kind, but the exact functional role of SLC37A3
remains unknown. For SLC37A1 we also observe expression in
the liver, kidney, intestine, and pancreas although the transcripts
in the liver and kidney constitute less than 2% of the level seen for
SLC37A4/G6PT. SLC37A1 is reported to be up-regulated by
epidermal growth factor in breast cancer cells, leading to the
suggestion that its biological role might be involved in phospho-
lipid biosynthesis [14]. For SLC37A2, expression has been
reported to be restricted to macrophages, spleen, and thymus
[15,17]. We find that SLC37A2 is also expressed in liver, kidney,
intestine, and pancreas but at levels less than 5% of those of
SLC37A4/G6PT. The report that SLC37A2 transcription is
markedly increased upon macrophage differentiation [17] may
point to a biological role with G6P in those cells. Together these
results suggest that only SLC37A4 is implicated in blood glucose
homeostasis and that the roles of the other SLC37 proteins lie in
cells outside the gluconeogenic tissues. It will be of interest in the
field to understand the physiological role of the other SLC37
proteins and determine if mutations underlie metabolic disorders
other than GSD-I.
In summary, we have shown that of the four members in the
SLC37 family, SLC37A1 and SLC37A2 exhibit a Pi-linked
G6P antiporter activity similar to that of the well characterized
SLC37A4/G6PT. However, their inability to couple with G6Pase-
a or G6Pase-b combined with their lack of sensitivity to CHA, and
Table 1. The mRNA levels of SLC37 members, relative to
G6PT/SLC37A4, in mouse liver, kidney, intestine, and
pancreas.
SLC37 members Liver Kidney Intestine Pancreas
% %%%
G6PT/SLC37A4 100 100 100 100
SLC37A1 0.960.2 1.660.2 59.865.8 68.8611.4
SLC37A2 1.360.2 1.060.2 4.462.8 3.860.4
SLC37A3 5.760.5 23.663.7 47.565.8 392.966.2
The expression levels of the SLC37A1, SLC37A2, SLC37A3, and G6PT/SLC37A4
transcripts were normalized to b-actin RNA and then scaled, for each tissue,
relative to the SLC37A4 transcript which was arbitrarily assigned as 100%.
Results reflect the average of three independent measurements of each
transcript and are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0023157.t001
Figure 4. Effects of CHA on antiporter activity of SLC37A1 and SLC37A2. Proteoliposomes were reconstituted from detergent solubilized
microsomal membrane extracts expressing SLC37A1, or SLC37A2 and were loaded with 50 mM Pi as described under Materials and Methods. The
50 mM Pi-loaded G6PT proteoliposomes were used as a control. Results shown are from three independent experiments, each point determined in
triplicate. Data are presented as the mean 6 SEM. **p,0.005.
doi:10.1371/journal.pone.0023157.g004
Figure 5. Effects of G6Pase-a and G6Pase-b on microsomal G6P
transport activity of SLC37A1, SLC37A2 and G6PT. Microsomal
membranes were isolated from COS-1 cells infected with Ad-G6Pase-a,
Ad-G6PT, Ad-SLC37A1-5Flag, or Ad-SLC37A2-5Flag, co-infected with
Ad-G6PT/Ad-G6Pase-a, Ad-SLC37A1-5Flag/Ad-G6Pase-a,o rA d -
SLC37A2-5Flag/Ad-G6Pase-a, or co-infected with Ad-G6PT/Ad-G6Pase-
b, Ad-SLC37A1-5Flag/Ad-G6Pase-b, or Ad-SLC37A2-5Flag/Ad-G6Pase-b
as described in Materials and Methods. Results represent three
independent experiments, with each data point determined in
triplicate. Data are presented as the mean 6 SEM. **p,0.005.
doi:10.1371/journal.pone.0023157.g005
SLC37A1 and SLC37A2 Are Antiporters
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their biological roles lie outside of blood glucose homeostasis.
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